Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK2 | P24941 | 13/20 | 0.68 |
| ▸ | CDK1 | P06493 | 14/20 | 0.58 |
| ▸ | CCNB1 | P14635 | 14/20 | 0.58 |
| ▸ | CCNA2 | P20248 | 12/20 | 0.58 |
| ▸ | CCNA1 | P78396 | 12/20 | 0.58 |
| ▸ | PIN1 | Q13526 | 1/20 | 0.56 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.46 |
| ▸ | GDA | Q9Y2T3 | 1/20 | 0.46 |
| ▸ | MAP3K5 | Q99683 | 1/20 | 0.44 |
| ▸ | DPP4 | P27487 | 1/20 | 0.44 |
| ▸ | MGMT | P16455 | 4/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Butylamine SCHEMBL27790885 | 0.86 | CDK2 (0.71) | CDK2CDK1CCNB1CCNA2CCNA1 | |
| Tetrabuthylammonium SCHEMBL200611 | 0.78 | CDK1 (0.39) | CDK2CDK1CCNB1CCNA2CCNA1 | |
| 6-O-Benzylguanine SCHEMBL10916361 | 0.75 | PIN1 (0.76) | CDK2CDK1CCNB1CCNA2CCNA1 | |
| Tetrabuthylammonium SCHEMBL3029323 | 0.72 | POLA1 (0.48) | CDK2CDK1CCNB1CCNA2CCNA1 | |
| SCHEMBL432161 | 0.71 | PAK1 (0.66) | CDK2CDK1CCNB1CCNA2CCNA1 | |
| SCHEMBL16146539 | 0.70 | HDAC1 (0.67) | CDK2CDK1CCNB1CCNA2CCNA1 | |
| SCHEMBL29720347 | 0.68 | MAP3K5 (0.60) | CDK2CDK1CCNB1CCNA2CCNA1 | |
| 2,6-Diaminopurine SCHEMBL28083713 | 0.67 | PDPK1 (0.79) | CDK2CDK1CCNB1CCNA2CCNA1 | |
| SCHEMBL8971208 | 0.67 | CDK1 (1.00) | CDK2CDK1CCNB1CCNA2CCNA1 | |
| SCHEMBL10580001 | 0.66 | PDPK1 (0.61) | CDK2CDK1CCNB1CCNA2CCNA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9005906-B2 | Tetrahydropyran nucleic acid analogs | ISIS PHARMACEUTICALS, INC. (US) | 2015-04-14 | — | — | US | disclosed |
| US-20140315979-A1 | TETRAHYDROPYRAN NUCLEIC ACID ANALOGS | ISIS PHARMACEUTICALS, INC. (US) | 2014-10-23 | — | — | US | disclosed |
| US-8796437-B2 | Tetrahydropyran nucleic acid analogs | ISIS PHARMACEUTICALS, INC. (US) | 2014-08-05 | — | — | US | disclosed |
| EP-2188298-B1 | TETRAHYDROPYRAN NUCLEIC ACID ANALOGS | ISIS PHARMACEUTICALS INC (US) | 2013-09-18 | — | — | EP | disclosed |
| US-20130211064-A1 | TETRAHYDROPYRAN NUCLEIC ACID ANALOGS | ISIS PHARMACEUTICALS, INC. (US) | 2013-08-15 | — | — | US | disclosed |
| US-8440803-B2 | Tetrahydropyran nucleic acid analogs | ISIS PHARMACEUTICALS, INC. (US) | 2013-05-14 | — | — | US | disclosed |
| US-20120071645-A1 | TETRAHYDROPYRAN NUCLEIC ACID ANALOGS | ISIS PHARMACEUTICALS, INC. (US) | 2012-03-22 | — | — | US | disclosed |
| US-20120021515-A1 | OLIGOMERIC COMPOUNDS AND METHODS | ISIS PHARMACEUTICALS, INC. | 2012-01-26 | — | — | US | disclosed |
| US-8088904-B2 | Tetrahydropyran nucleic acid analogs | ISIS PHARMACEUTICALS, INC. (US) | 2012-01-03 | — | — | US | disclosed |
| EP-2188298-A2 | TETRAHYDROPYRAN NUCLEIC ACID ANALOGS | Isis Pharmaceuticals, Inc. (US) | 2010-05-26 | — | — | EP | disclosed |
| WO-2009143369-A2 | METHOD OF PREPARING NUCLEOSIDES AND ANALOGS THEREOF WITHOUT USING CHROMATOGRAPHY | ISIS PHARMACEUTICALS, INC. (US) | 2009-11-26 | — | — | WO | disclosed |
| US-20090092981-A1 | TETRAHYDROPYRAN NUCLEIC ACID ANALOGS | IONIS PHARMACEUTICALS, INC. | 2009-04-09 | — | — | US | disclosed |
| WO-2009023855-A2 | TETRAHYDROPYRAN NUCLEIC ACID ANALOGS | ISIS PHARMACEUTICALS, INC. (US) | 2009-02-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120021515-A1 | OLIGOMERIC COMPOUNDS AND METHODS | HNRNPH1, RNASEH1, SNRPE | CDK2 2349/4885CDK1 2888/4885CCNB1 2409/4885 |
| US-20120071645-A1 | TETRAHYDROPYRAN NUCLEIC ACID ANALOGS | HNRNPM, POLM, RNMT | CDK2 1068/4885CDK1 2435/4885CCNB1 2843/4885 |
| US-20090092981-A1 | TETRAHYDROPYRAN NUCLEIC ACID ANALOGS | HNRNPM, POLM, RNMT | CDK2 1068/4885CDK1 2435/4885CCNB1 2843/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.